Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.20
Views: 159

Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom

Dr Syed Hussain speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the NEO-BLADE trial which is a phase II randomised placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer.

He reports that the trial failed to reach its primary endpoint of demonstrating an improvement in pathological complete response but did meet the secondary endpoints by demonstrating improvements for nintedanib over placebo in both progression free survival and overall survival.

Dr Hussain explains that previous similar studies had to be stopped early due to toxicity fears however this study was able to demonstrate a well-tolerated regimen with well-balanced toxicities.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation